Sponsored · Video
Polaryx Therapeutics Boosts Lysosome Biogenesis to Treat Neurodegenerative Disorders
Hahn-Jun Lee, President and CEO of Polaryx Therapeutics Inc., speaks at BIO-Europe® 2019 in Hamburg about how the company accelerates the availability of treatment options for underserved patients, and what the scientific rationale is behind their products. Polaryx Therapeutics’ core platform aims to boost lysosome biogenesis via PPARα-dependent TFEB upregulation. This approach will contribute to the development of the right solutions to help patients suffering from lysosomal storage disorders and neurodegenerative disorders. Lee also discusses the clinical trials his development team is currently working on and those on the horizon for 2020.